Autoimmune hepatitis Diagnostic of choice: Difference between revisions

Jump to navigation Jump to search
 
(10 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Autoimmune hepatitis}}
{{Autoimmune hepatitis}}
{{CMG}}; {{AE}}:{{MKK}}
{{CMG}}; {{AE}}{{MKK}}
==Overview==
==Overview==
[[Liver biopsy]] is the gold standard test for the diagnosis of [[autoimmune hepatitis]]. Interface [[hepatitis]] (ie, piecemeal [[necrosis]]) is the histological hallmark of [[autoimmune hepatitis]]. In [[cirrhosis]], [[fibrosis]], bridging [[necrosis]] are usually found. Liver biospy is also used to diagnose overlap syndrome.
== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==
=== Gold standard/Study of choice: ===
*[[Liver biopsy]] is the gold standard test for the diagnosis of [[autoimmune hepatitis]]<ref name="pmid12362575">{{cite journal |vauthors=Carpenter HA, Czaja AJ |title=The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants |journal=Clin Liver Dis |volume=6 |issue=3 |pages=685–705 |year=2002 |pmid=12362575 |doi= |url=}}</ref><ref name="pmid17051746">{{cite journal |vauthors=Szabó Z |title=[The role of liver biopsy in the diagnosis of autoimmune hepatitis] |language=Hungarian |journal=Orv Hetil |volume=147 |issue=35 |pages=1697–702 |year=2006 |pmid=17051746 |doi= |url=}}</ref><ref name="pmid21674554">{{cite journal |vauthors=Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Lucena MI, Castiella A, Lindor K, Björnsson E |title=The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury |journal=Hepatology |volume=54 |issue=3 |pages=931–9 |year=2011 |pmid=21674554 |pmc=3192933 |doi=10.1002/hep.24481 |url=}}</ref><ref name="pmid26642062">{{cite journal |vauthors=Tiniakos DG, Brain JG, Bury YA |title=Role of Histopathology in Autoimmune Hepatitis |journal=Dig Dis |volume=33 Suppl 2 |issue= |pages=53–64 |year=2015 |pmid=26642062 |doi=10.1159/000440747 |url=}}</ref>
*[[Liver biopsy]] is the gold standard test for the diagnosis of [[autoimmune hepatitis]]<ref name="pmid12362575">{{cite journal |vauthors=Carpenter HA, Czaja AJ |title=The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants |journal=Clin Liver Dis |volume=6 |issue=3 |pages=685–705 |year=2002 |pmid=12362575 |doi= |url=}}</ref><ref name="pmid17051746">{{cite journal |vauthors=Szabó Z |title=[The role of liver biopsy in the diagnosis of autoimmune hepatitis] |language=Hungarian |journal=Orv Hetil |volume=147 |issue=35 |pages=1697–702 |year=2006 |pmid=17051746 |doi= |url=}}</ref><ref name="pmid21674554">{{cite journal |vauthors=Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Lucena MI, Castiella A, Lindor K, Björnsson E |title=The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury |journal=Hepatology |volume=54 |issue=3 |pages=931–9 |year=2011 |pmid=21674554 |pmc=3192933 |doi=10.1002/hep.24481 |url=}}</ref><ref name="pmid26642062">{{cite journal |vauthors=Tiniakos DG, Brain JG, Bury YA |title=Role of Histopathology in Autoimmune Hepatitis |journal=Dig Dis |volume=33 Suppl 2 |issue= |pages=53–64 |year=2015 |pmid=26642062 |doi=10.1159/000440747 |url=}}</ref>
*Liver biopsy is performed by following methods:
*Liver biopsy is performed by following methods:
Line 10: Line 10:
**Transjugular liver biopsy
**Transjugular liver biopsy
Histology findings usually found on biopsy:
Histology findings usually found on biopsy:
*Interface hepatitis (ie, piecemeal necrosis) is the histological hallmark
*Interface [[hepatitis]] (ie, piecemeal [[necrosis]]) is the histological hallmark.
**Portal lesion spares the [[biliary tree]]
**Portal lesion spares the [[biliary tree]]
**This involves most of the [[lobule]]
**This involves most of the [[lobule]]
**Lobular collapse which is best identified by reticulin staining
**Lobular collapse which is best identified by reticulin staining.
**There is lymphoplasmacytic periportal infiltrate which invade the limiting plate
**There is lymphoplasmacytic periportal infiltrate which invade the limiting plate.
**There is an abundance of [[plasma cells]] and [[eosinophils]] are usually present
**There is an abundance of [[plasma cells]] and [[eosinophils]] are usually present.
*A plasma cell infiltrate lead to plasma cell [[hepatitis]] If it involves lobules called lobular or whole liver known as panacinar [[hepatitis]]
*A plasma cell infiltrate lead to plasma cell [[hepatitis]], If it involves lobules called lobular or whole liver known as panacinar [[hepatitis]].
In [[cirrhosis]]following findings are seen on biopsy:
In [[cirrhosis]] following findings are seen on biopsy:
*[[Fibrosis]]
*[[Fibrosis]]
*Bridging [[necrosis]]
*Bridging [[necrosis]]


==Overlap syndrome==
==Overlap syndrome==
Liver biospy is gold standard for diagnosing overlap syndrome<ref name="pmid20101749">{{cite journal |vauthors=Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ |title=Diagnosis and management of primary sclerosing cholangitis |journal=Hepatology |volume=51 |issue=2 |pages=660–78 |year=2010 |pmid=20101749 |doi=10.1002/hep.23294 |url=}}</ref><ref name="pmid12122860">{{cite journal |vauthors=Dienes HP, Erberich H, Dries V, Schirmacher P, Lohse A |title=Autoimmune hepatitis and overlap syndromes |journal=Clin Liver Dis |volume=6 |issue=2 |pages=349–62, vi |year=2002 |pmid=12122860 |doi= |url=}}</ref>
Liver biospy is also used to diagnose overlap syndrome:<ref name="pmid20101749">{{cite journal |vauthors=Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ |title=Diagnosis and management of primary sclerosing cholangitis |journal=Hepatology |volume=51 |issue=2 |pages=660–78 |year=2010 |pmid=20101749 |doi=10.1002/hep.23294 |url=}}</ref><ref name="pmid12122860">{{cite journal |vauthors=Dienes HP, Erberich H, Dries V, Schirmacher P, Lohse A |title=Autoimmune hepatitis and overlap syndromes |journal=Clin Liver Dis |volume=6 |issue=2 |pages=349–62, vi |year=2002 |pmid=12122860 |doi= |url=}}</ref>
{| class="wikitable"
{| class="wikitable"
! colspan="2" | '''Histology findings of overlap syndrome'''
! colspan="2" | '''Histology findings of overlap syndrome'''
Line 31: Line 31:
|AIH-PBC
|AIH-PBC
|
|
* Interface hepatitis
* Interface [[hepatitis]]
* Destructive cholangitis (florid duct lesions) 
* Destructive [[cholangitis]] (florid duct lesions) 
|-
|-
|AIH-PSC
|AIH-PSC
|
|
* Interface hepatitis
* Interface [[hepatitis]]


* Ductopenia  
* Ductopenia  
Line 42: Line 42:
* Portal edema or fibrous  
* Portal edema or fibrous  


* Obliterative fibrous cholangitis (rare)
* Obliterative fibrous [[cholangitis]] (rare)
|-
|-
|AIH-cholestatic syndrome
|AIH-cholestatic syndrome
|
|
* Interface hepatitis  
* Interface [[hepatitis]]


* Destructive cholangitis or bile duct loss
* Destructive [[cholangitis]] or bile duct loss
|}
|}



Latest revision as of 17:27, 9 January 2018

Autoimmune hepatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating autoimmune hepatitis differential diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Diagnostic of choice

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune hepatitis Diagnostic of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune hepatitis Diagnostic of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune hepatitis Diagnostic of choice

CDC on Autoimmune hepatitis Diagnostic of choice

Autoimmune hepatitis Diagnostic of choice in the news

Blogs on Autoimmune hepatitis Diagnostic of choice

Directions to Hospitals Treating Autoimmune hepatitis

Risk calculators and risk factors for Autoimmune hepatitis Diagnostic of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Liver biopsy is the gold standard test for the diagnosis of autoimmune hepatitis. Interface hepatitis (ie, piecemeal necrosis) is the histological hallmark of autoimmune hepatitis. In cirrhosis, fibrosis, bridging necrosis are usually found. Liver biospy is also used to diagnose overlap syndrome.

Diagnostic Study of Choice

Histology findings usually found on biopsy:

  • Interface hepatitis (ie, piecemeal necrosis) is the histological hallmark.
    • Portal lesion spares the biliary tree
    • This involves most of the lobule
    • Lobular collapse which is best identified by reticulin staining.
    • There is lymphoplasmacytic periportal infiltrate which invade the limiting plate.
    • There is an abundance of plasma cells and eosinophils are usually present.
  • A plasma cell infiltrate lead to plasma cell hepatitis, If it involves lobules called lobular or whole liver known as panacinar hepatitis.

In cirrhosis following findings are seen on biopsy:

Overlap syndrome

Liver biospy is also used to diagnose overlap syndrome:[5][6]

Histology findings of overlap syndrome
Types Biopsy findings
AIH-PBC
AIH-PSC
  • Ductopenia
  • Portal edema or fibrous
AIH-cholestatic syndrome

References

  1. Carpenter HA, Czaja AJ (2002). "The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants". Clin Liver Dis. 6 (3): 685–705. PMID 12362575.
  2. Szabó Z (2006). "[The role of liver biopsy in the diagnosis of autoimmune hepatitis]". Orv Hetil (in Hungarian). 147 (35): 1697–702. PMID 17051746.
  3. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Lucena MI, Castiella A, Lindor K, Björnsson E (2011). "The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury". Hepatology. 54 (3): 931–9. doi:10.1002/hep.24481. PMC 3192933. PMID 21674554.
  4. Tiniakos DG, Brain JG, Bury YA (2015). "Role of Histopathology in Autoimmune Hepatitis". Dig Dis. 33 Suppl 2: 53–64. doi:10.1159/000440747. PMID 26642062.
  5. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010). "Diagnosis and management of primary sclerosing cholangitis". Hepatology. 51 (2): 660–78. doi:10.1002/hep.23294. PMID 20101749.
  6. Dienes HP, Erberich H, Dries V, Schirmacher P, Lohse A (2002). "Autoimmune hepatitis and overlap syndromes". Clin Liver Dis. 6 (2): 349–62, vi. PMID 12122860.

Template:WS Template:WH